NIAID Awards $3.7M Task Order to Leidos Biomedical for COVID-19 R&D Efforts

Contract Overview

Contract Amount: $291,244,978 ($291.2M)

Contractor: Leidos Biomedical Research Inc

Awarding Agency: Department of Health and Human Services

Start Date: 2020-08-31

End Date: 2024-08-30

Contract Duration: 1,460 days

Daily Burn Rate: $199.5K/day

Competition Type: FULL AND OPEN COMPETITION

Pricing Type: COST PLUS FIXED FEE

Sector: R&D

Official Description: NIAID DCR OPERATIONAL TASK ORDER COVID FUNDING IN THE AMOUNT OF $3,706,224 FOR COVID RELATED EFFORTS ON THIS TASK ORDER

Place of Performance

Location: FREDERICK, FREDERICK County, MARYLAND, 21702

State: Maryland Government Spending

Plain-Language Summary

Department of Health and Human Services obligated $291.2 million to LEIDOS BIOMEDICAL RESEARCH INC for work described as: NIAID DCR OPERATIONAL TASK ORDER COVID FUNDING IN THE AMOUNT OF $3,706,224 FOR COVID RELATED EFFORTS ON THIS TASK ORDER Key points: 1. Spending focuses on COVID-19 related research and development, a critical area. 2. Leidos Biomedical Research Inc. is a significant player in health and biomedical services. 3. The contract is a delivery order under a larger contract, indicating potential for follow-on work. 4. The R&D sector is characterized by innovation but also inherent project risks.

Value Assessment

Rating: fair

The $3.7M task order is for specific COVID-19 efforts. Benchmarking against similar R&D task orders is difficult without more detailed scope information, but the amount appears reasonable for specialized research support.

Cost Per Unit: N/A

Competition Analysis

Competition Level: full-and-open

The contract was awarded under full and open competition, suggesting a competitive bidding process. This method generally promotes price discovery and potentially better value for the government.

Taxpayer Impact: The funding supports critical COVID-19 research, aiming for advancements that could benefit public health, justifying the taxpayer investment.

Public Impact

Supports ongoing research into COVID-19, contributing to national health security. Funds critical operational tasks for the National Institutes of Health (NIH). The award to Leidos Biomedical Research Inc. highlights their role in government health initiatives. Potential for advancements in understanding and combating the virus.

Waste & Efficiency Indicators

Waste Risk Score: 50 / 10

Warning Flags

Positive Signals

Sector Analysis

This award falls within the Research and Development sector, specifically for physical, engineering, and life sciences. Spending in this area is crucial for innovation but can be subject to project-specific risks and evolving scientific needs.

Small Business Impact

The data indicates this contract was not awarded to a small business (ss: false, sb: false). There is no direct analysis of small business participation in this specific task order.

Oversight & Accountability

The task order is managed by the National Institutes of Health (NIH), a component of HHS, which has established oversight mechanisms for research grants and contracts. Accountability is tied to the delivery of research objectives.

Related Government Programs

Risk Flags

Tags

research-and-development-in-the-physical, department-of-health-and-human-services, md, delivery-order, 100m-plus

Frequently Asked Questions

What is this federal contract paying for?

Department of Health and Human Services awarded $291.2 million to LEIDOS BIOMEDICAL RESEARCH INC. NIAID DCR OPERATIONAL TASK ORDER COVID FUNDING IN THE AMOUNT OF $3,706,224 FOR COVID RELATED EFFORTS ON THIS TASK ORDER

Who is the contractor on this award?

The obligated recipient is LEIDOS BIOMEDICAL RESEARCH INC.

Which agency awarded this contract?

Awarding agency: Department of Health and Human Services (National Institutes of Health).

What is the total obligated amount?

The obligated amount is $291.2 million.

What is the period of performance?

Start: 2020-08-31. End: 2024-08-30.

What specific COVID-19 research activities does this $3.7M task order fund?

The provided data does not specify the exact research activities funded by this $3.7M task order. It broadly states 'COVID related efforts.' Further details would be needed from the contract's statement of work to understand the precise nature of the research, such as vaccine development, therapeutic testing, epidemiological studies, or diagnostic research.

What are the primary risks associated with this R&D task order?

Key risks include the inherent uncertainty in research and development outcomes, potential for scope creep as research progresses, and the possibility of cost overruns if research proves more complex than anticipated. There's also a risk related to the timely delivery of research findings crucial for public health responses.

How does this funding contribute to the overall effectiveness of the NIH's COVID-19 response?

This funding contributes to the effectiveness of the NIH's COVID-19 response by supporting essential operational tasks and research efforts. By contracting with Leidos Biomedical Research Inc., the NIH can leverage specialized expertise and resources to accelerate progress in understanding and combating the virus, ultimately aiding in the development of countermeasures and public health strategies.

Industry Classification

NAICS: Professional, Scientific, and Technical ServicesScientific Research and Development ServicesResearch and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

Product/Service Code: RESEARCH AND DEVELOPMENTN – Health R&D Services

Competition & Pricing

Extent Competed: FULL AND OPEN COMPETITION

Solicitation Procedures: NEGOTIATED PROPOSAL/QUOTE

Pricing Type: COST PLUS FIXED FEE (U)

Evaluated Preference: NONE

Contractor Details

Parent Company: Leidos Holdings, Inc.

Address: 1050 BOYLES ST, FREDERICK, MD, 21702

Business Categories: Category Business, Corporate Entity Not Tax Exempt, Not Designated a Small Business, Special Designations, U.S.-Owned Business

Financial Breakdown

Contract Ceiling: $297,601,688

Exercised Options: $297,601,688

Current Obligation: $291,244,978

Actual Outlays: $223,133,388

Subaward Activity

Number of Subawards: 21

Total Subaward Amount: $38,744,486

Contract Characteristics

Commercial Item: COMMERCIAL PRODUCTS/SERVICES PROCEDURES NOT USED

Cost or Pricing Data: YES

Parent Contract

Parent Award PIID: 75N91019D00024

IDV Type: IDC

Timeline

Start Date: 2020-08-31

Current End Date: 2024-08-30

Potential End Date: 2024-08-30 00:00:00

Last Modified: 2024-06-06

More Contracts from Leidos Biomedical Research Inc

View all Leidos Biomedical Research Inc federal contracts →

Other Department of Health and Human Services Contracts

View all Department of Health and Human Services contracts →

Explore Related Government Spending